We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Researchers Discover World’s First Human Antibody that Could Inhibit New Coronavirus (SARS-CoV-2)

By LabMedica International staff writers
Posted on 14 Mar 2020
Researchers have developed the world’s first human antibody that could inhibit the new coronavirus (SARS-CoV-2) and ‘offers potential for prevention and treatment of COVID-19’. More...
A team of 10 scientists from the University of Utrecht (Utrecht, the Netherlands), the Erasmus Medical Centre (Rotterdam, the Netherlands), and biotech company Harbor BioMed (Cambridge, MA, USA) have published their research online on BioRxiv where it is under peer review before being published by the prestigious journal Nature.

During their earlier work on developing antibodies against MERS, SARS and another Hong Kong coronavirus (OC-43), the researchers had found antibodies that cross-reacted with those three different viruses and kept them from infecting. The researchers had stored the untested antibodies that did not react with all the three mutations, but did with SARS1, in the refrigerator. After the SARS2 crisis broke out, they immediately tested whether the antibodies that reacted with SARS1 also responded to SARS2 and then found the antibody that has now been published.

The researchers are now making efforts to tie up with a pharmaceutical company that can produce the antibody on a large scale as a medicine. According to the researchers, the antibody offers potential for the development of a medicine as well as a diagnostic test that everyone can perform at home to easily confirm if they are infected or not. However, before it can be marketed, the antibody is currently being made to undergo rigorous development and tests for toxicological properties which should take a few more months.

Related Links:
University of Utrecht
Erasmus Medical Centre
Harbor BioMed



Gold Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Online QC Software
Acusera 24•7
Manual Pipetting Aid
Pipette Controllers macro
New
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Illustration of the new blood test, which uses a DNA chip to detect the tumor’s biological fingerprint (Photo courtesy of Tel Aviv University)

Blood Test on a Chip Offers Low-Cost Lung Cancer Detection Without DNA Sequencing

Lung cancer is the leading cause of cancer deaths worldwide, and screening often yields indeterminate results that prompt invasive workups. Computed tomography (CT) detects small nodules but can flag benign... Read more

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

Whole-Cell Genomic Analysis Expands the Potential of Liquid Biopsy

Liquid biopsy has expanded access to tumor genomics, but most blood-based assays rely on short, degraded fragments of cell-free circulating tumor DNA (ctDNA). Isolating intact circulating tumor cells from... Read more

Microbiology

view channel
Image: An innovative countywide program in Taiwan combines risk-based screening with decentralized community care to improve hepatitis C detection and treatment (Image Credit: iStock)

Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps

Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. Although highly effective... Read more

Pathology

view channel
Image: Through the PCCP, Proscia gains a more efficient pathway to expand Concentriq AP-Dx interoperability while maintaining regulatory oversight (Photo courtesy of Proscia)

FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis

Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.